Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Latest Disclosed Ownership106,592 shares
Latest Disclosed Value $ 35,268,095
Bridgewater Associates, LP reports 24.50% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Bridgewater Associates, LP filed a 13F-HR form disclosing ownership of 106,592 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $30,453,334 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 85,617 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 24.50% during the quarter. The current value of the position is $27,767,216 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 106,592 20,975 24.50 35,268 3.59 0.1574
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 85,617 51,706 152.48 34,046 120.17 0.1242
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,911 33,911 15,463 0.0606
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -6,452 -100.00 0 -100.00
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,452 4,450 222.28 1,518 176.00 0.0070
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,002 2,002 551 0.0031
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,951 -100.00 0 -100.00
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,951 65 3.45 373 11.68 0.0021
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,886 90 5.01 334 -2.05 0.0020
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,796 541 43.11 341 35.86 0.0021
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,255 1,255 251 0.0015
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,283 -100.00 0 -100.00
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,283 -229 -15.15 257 16.29 0.0013
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,512 1,512 221 0.0009
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,234 -100.00 0 -100.00
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,234 -3,865 -63.37 422 -59.19 0.0023
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,099 6,099 1,034 0.0066
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.